CLINICAL TRIALS AND OBSERVATIONS Iron chelation therapy with deferasirox in patients with aplastic anemia: a subgroup analysis of 116 patients from the EPIC trial

نویسندگان

  • Jong Wook Lee
  • Sung-Soo Yoon
  • Zhi Xiang Shen
  • Arnold Ganser
  • Hui-Chi Hsu
  • Dany Habr
  • Gabor Domokos
  • Bernard Roubert
  • John B. Porter
چکیده

1The Catholic University of Korea, Seoul, South Korea; 2Seoul National University College of Medicine, Seoul, South Korea; 3Ruijin Hospital, Shanghai Second Medical University, Shanghai, China; 4Medizinische Hochschule Hannover, Hannover, Germany; 5Taipei City Hospital, Taipei, Taiwan; 6Novartis Pharmaceuticals, East Hanover, NJ; 7Novartis Pharma AG, Basel, Switzerland; and 8University College London, London, United Kingdom

برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

ثبت نام

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

منابع مشابه

CLINICAL TRIALS AND OBSERVATIONS Effect of transfusional iron intake on response to chelation therapy in -thalassemia major

The success of chelation therapy in controlling iron overload in patients with thalassemia major is highly variable and may partly depend on the rate of transfusional iron loading. Using data from the 1-year phase III study of deferasirox, including volumes of transfused red blood cells and changes in liver iron concentration (LIC) in 541 patients, the effect of iron loading on achieving neutra...

متن کامل

CLINICAL TRIALS AND OBSERVATIONS Stroke With Transfusions Changing to Hydroxyurea (SWiTCH)

Stroke is a devastating complication of sickle cell anemia (SCA) with high recurrence if untreated. Chronic transfusions reduce recurrent strokes but have associated morbidities including iron overload. Stroke With Transfusions Changing to Hydroxyurea (SWiTCH) was a multicenter phase 3 randomized trial comparing standard treatment (transfusions/chelation) to alternative treatment (hydroxyurea/p...

متن کامل

CLINICAL TRIALS AND OBSERVATIONS Iron chelation with deferasirox in adult and pediatric patients with thalassemia major: efficacy and safety during 5 years’ follow-up

1Universitá di Milano, Ca Granda Foundation Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS), Milan, Italy; 2Centre National de Greffe de Moelle Osseuse, Bab Saadoun, Tunis, Tunisia; 3Istanbul University Medical Faculty, Istanbul, Turkey; 4Suleyman Demirel University Medical Faculty, Isparta, Turkey; 5Ospedale Civico, G Di Cristina e Benfratelli, Palermo, Italy; 6Children’s Hospital ...

متن کامل

Plenary Paper CLINICAL TRIALS AND OBSERVATIONS A 1-year randomized controlled trial of deferasirox vs deferoxamine for myocardial iron removal in b-thalassemia major (CORDELIA)

A 1-year randomized controlled trial of deferasirox vs deferoxamine for myocardial iron removal in b-thalassemia major (CORDELIA) Dudley J. Pennell, John B. Porter, Antonio Piga, Yongrong Lai, Amal El-Beshlawy, Khawla M. Belhoul, Mohsen Elalfy, Akif Yesilipek, Yurdanur Kilinç, Tomasz Lawniczek, Dany Habr, Marianne Weisskopf, Yiyun Zhang, and Yesim Aydinok, on behalf of the CORDELIA study invest...

متن کامل

CLINICAL TRIALS AND OBSERVATIONS High-dose cyclophosphamide for severe aplastic anemia: long-term follow-up

Severe aplastic anemia (SAA) is a lifethreatening bone marrow failure disorder that can be treated with bone marrow transplantation, immunosuppressive therapy,and high-dose cyclophosphamide. Here, we report long-term follow-up on 67 SAA patients (44 treatment-naiveand23refractory) treated with high-dose cyclophosphamide. At 10 years, the overall actuarial survival was 88%, the response rate was...

متن کامل

ذخیره در منابع من


  با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید

برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

ثبت نام

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

عنوان ژورنال:

دوره   شماره 

صفحات  -

تاریخ انتشار 2010